More than a decade of Drugs to Watch
Our picks, from 2013 to the present.
In identifying our 2025 Drugs to Watch, we drew on the expertise of more than 160 Clarivate analysts and 11 integrated data sets spanning hundreds of drugs, diseases and markets and covering the whole of the innovation lifecycle.
| Drug Name | Company | Therapy Area | Year |
| Patisiran (Onpattro) | Alnylam Pharmaceuticals Inc., Sanofi Genzyme | Genetic disorder | 2018 |
| Shingrix vaccine | GlaxoSmithKline plc | Infectious disease | 2018 |
| Ertugliflozin (Steglatro) | Merck & Co., Pfizer Inc. | Endocrinology/metabolic disease | 2018 |
| Alirocumab (Praluent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Cardiovascular disease | 2015 |
| Brexpiprazole (Rexulti) | Lundbeck, Otsuka Pharmaceutical | Neurology/psychiatric | 2015 |
| Evolocumab (Repatha) | Amgen, Astellas Pharma Inc. | Cardiovascular disease | 2015 |
| Lumacaftor plus ivacaftor (Orkambi) | Vertex Pharmaceuticals Inc. | Respiratory disease | 2015 |
| Nivolumab (Opdivo) | Bristol-Myers Squibb Co. | Oncology | 2015 |
| Palbociclib (Ibrance) | Pfizer Inc. | Oncology | 2015 |
| Sacubitril plus valsartan (LCZ-696) | Novartis International AG | Cardiovascular disease | 2015 |
| Secukinumab (Cosentyx) | Novartis International AG | Excessive immune response/autoimmunity | 2015 |
| Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak) | AbbVie Inc. | Respiratory disease | 2015 |
| Mirikizumab | Eli Lilly and Co. | Crohn’s disease and ulcerative colitis | 2023, 2024 |
| Faricimab | Roche and Chugai Pharmaceutical | Diabetic macular edema, Wet age-related macular degeneration | 2022 |
| Adagrasib | Mirati Therapeutics, Zai Lab Limited | KRASG12C-positive NSCLC and CRC | 2022 |
| Vutrisiran | Alnylam Pharmaceuticals Inc. | Transthyretin-mediated amyloidosis-related polyneuropathy | 2022 |
| Tirzepatide | Eli Lilly and Co. | Type 2 diabetes mellitus (T2DM) | 2022 |
| Tezepelumab | Amgen, AstraZeneca plc | Severe asthma | 2022 |
| Teclistamab | Janssen Pharmaceutical Companies of Johnson & Johnson | Multiple myeloma | 2023 |
| Valoctocogene roxaparvovec | Biomarin Pharmaceutical Inc. | Hemophilia A | 2023 |
| Teplizumab | Provention Bio Inc | Type 1 diabetes mellitus (T1DM) | 2023 |
| Sparsentan | Travere Therapeutics Inc | Focal segmental glomerulosclerosis (FSGS), IgA nephropathy | 2023 |
| Ritlecitinib | Pfizer Inc. | Alopecia areata | 2023 |
| Pegcetacoplan | Apellis Pharmaceuticals Inc. | Geographic atrophy (GA), Paroxysmal nocturnal hemoglobinuria (PNH) | 2023 |
| Lenacapavir | Gilead Sciences Inc. | HIV | 2023 |
| Aducanumab | Biogen Inc., Esai Co Ltd. | Alzheimer’s disease, Neurology/psychiatric | 2021 |
| Trastuzumab deruxtecan (DS-8201a; Enhertu) | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Oncology | 2020 |
| Vadadustat | Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | Chronic disease complication | 2020 |
| Valoctocogene roxaparvovec (BMN-270; Valrox) | Biomarin Pharmaceutical Inc. | Genetic disorder | 2020 |
| Betibeglogene darolentivec (LentiGlobin) | Bluebird Bio Inc. | Genetic disorder | 2019 |
| Onasemnogene abeparvovec (AVXS-101; Zolgensma) | AveXis | Genetic disorder | 2019 |
| Palforzia (AR101; Aerumab) | Aimmune Therapeutics | Excessive immune response/autoimmunity | 2019 |
| Ravulizumab (ALXN-1210; Ultomiris) | Alexion Pharmaceuticals Inc. | Excessive immune response/autoimmunity, Genetic disorder | 2019 |
| Risankizumab (BI-655066; ABBV-066; Skyrizi) | AbbVie Inc., Boehringer Ingelheim | Excessive immune response/autoimmunity | 2019 |
| Roxadustat (FG-4592; AZD-9941; ASP-1517; Ai Rui Zhuo) | Astellas Pharma Inc., AstraZeneca plc, FibroGen | Chronic disease complication | 2019 |
| Upadacitinib (ABT-494; Rinvoq) | AbbVie Inc. | Excessive immune response/autoimmunity | 2019 |
| Tenofovir alafenamide plus emtricitabine plus bictegravir (Biktarvy) | Gilead Sciences Inc. | Infectious disease | 2018 |
| Avelumab (Bavencio) | Merck Serono, Pfizer Inc. | Oncology | 2017 |
| Axicabtagene ciloleucel (KTE-C19; Yescarta) | Kite Pharma | Oncology | 2017 |
| Baricitinib (Olumiant) | Eli Lilly and Co., Incyte Corp. | Excessive immune response/autoimmunity | 2017 |
| Dupilumab (Dupixent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Excessive immune response/autoimmunity | 2017 |
| Durvalumab (Imfinzi) | AstraZeneca plc | Oncology | 2017 |
| Niraparib (Zejula) | Tesaro | Oncology | 2017 |
| Ocrelizumab (Ocrevus) | Roche | Neurology/psychiatric | 2017 |
| Ribociclib (LEE-011; Kisqali) | Novartis International AG | Oncology | 2017 |
| Semaglutide (Ozempic) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2017 |
| Gardasil 9 vaccine | Merck & Co. | Infectious disease | 2015 |
| Insulin glargine (Toujeo) | Sanofi SA | Endocrinology/metabolic disease | 2015 |
| Relugolix | ASKA Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. | Endometriosis & uterine fibroids, Oncology, Prostate cancer, Reproductive health | 2021 |
| Vericiguat | Bayer AG, Merck & Co. | Cardiovascular – heart failure | 2021 |